Retrospective Cohort Analysis of Neoadjuvant Treatment and Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma in a High Volume Referral Centre.

Malinda Itchins,Jennifer Arena,Joel Rabindran,Nahm Christopher, Sia Kim,Emma Gibbs,Anthony J. Gill,Richard Maher,Geoffrey Schembri,Elizabeth Bailey,Anubhav Mittal,Sarah Bergamin,Matthew Wong,George Hruby,Andrew Kneebone,Nick Pavlakis,Jaswinder S. Samra,Stephen Clarke

Journal of clinical oncology（2017）

引用 24|浏览11

暂无评分

摘要

395Background: The 5 year (yr) overall survival (OS) of pancreas cancer (PC) is < 5%. Surgical resection is the only curative treatment (tx), most relapse within 2yrs. Neoadjuvant (NA) tx can benef...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要